Current guidelines for the management of hypercholesterolemia identify LDL cholesterol (LDL-c) reduction as the primary therapeutic target and have highlighted the need to use statins to achieve it.
There are six statins with four different doses and with different power-reducing LDL-c. By adding ezetimibe, there are 48 therapeutic possibilities.
This extensive offer provides pharmaceutical treatment, but it is difficult to choose the most cost-effective statin because it is very difficult to remember all the powers and costs of treatment options.
This paper offers a method to prioritize the best cost-effective lipid lowering, and chooses the cheapest statin that achieves the desired therapeutic goal of LDL-c.
2011-06-07
Spa.
Medicina clinica
Unidad de Lípidos y Prevención Cardiovascular, Centro de Salud Pinto, Dirección Asistencial 4 SUR, SERMAS, Madrid, España. antoniodoctor [at] gmail.com
Med Clin (Barc). 2011 Jun;137(3):119-25
© Galenicom 1999-2013